Summary Previously we found that the Ishikawa endometrial cancer cell line expresses macrophage colonystimulating factor (M-CSF) and c-fms transcripts and that its proliferation is enhanced by the addition of recombinant M-CSF. This suggested that Ishikawa cells are constitutively stimulated by M-CSF. In support of this we now show that Ishikawa cells secrete M-CSF and that known stimulators of M-CSF production increase the amount detected in Ishikawa cell conditioned medium. Using retroviral infections to introduce and express exogenous c-fms genes in Ishikawa cells we also demonstrate proliferation to be partially inhibited by a dominant negative, mutant c-fms gene, yet enhanced approximately 3-fold by a normal c-fms gene, under conditions in which the only source of M-CSF was that produced by the cells. The data provide evidence for the existence of an active M-CSF/receptor loop in these endometrial cancer cells and suggests the possibility of such activity in tumours of the endometrium and ovary that aberrantly express M-CSF and fins genes.
The sex steroid hormones oestradiol and progesterone regulate the synthesis of locally acting polypeptide growth factors and their receptors (Pollard, 1991; Giudice, 1994) , and therefore potentially have indirect as well as direct effects upon uterine growth and differentiation. Macrophage colonystimulating factor (M-CSF) was initially demonstrated to be under sex-steroid hormone control in the mouse uterus and to be elevated during pregnancy (Pollard et al., 1987; Arceci et al., 1989) whereas its receptor, encoded by the protooncogene c-fms (Sherr et al., 1985) , was expressed in trophoblast cells (Arceci et al., 1989; Regenstrief and Rossant, 1989) . Subsequently, M-CSF and its receptor have been suggested as local mediators at the feto-maternal interface on the basis of their expression in the pregnant endometrium and trophoblast respectively (Kauma et al., 1991; Daiter et al., 1992; Pampfer et al., 1992; Jokhi et al., 1993) . The expression of M-CSF and c-fms is not however restricted to pregnancy as low-level expression of each transcript has been detected in normal endometrium (Kauma et al., 1991; Daiter et al., 1992; Pampfer et al., 1992) .
The level of expression of M-CSF and c-fms in endometrial cancer is greater than in normal and benign tissue specimens; co-expression of M-CSF and c-fms is frequently observed in endometrial adenocarcinomas and is correlated with adverse prognostic indicators (Kacinski et al., 1988; Baiocchi et al., 1991; Leiserowitz et al., 1993) . Elevated serum M-CSF is a feature of endometrial cancer patients and is suggested to be a circulating tumour marker of neoplastic disease activity (Kacinski et al., 1990) . Such observations have led these authors to suggest that overexpression of M-CSF and c-fms contributes to the development and progression of endometrial cancer. We have previously reported on the expression of M-CSF and c-fms mRNA in the human endometrial adenocarcinoma cell line, Ishikawa, and demonstrated increased cellular proliferation in response to recombinant human (rh) M-CSF (Croxtall et al., 1992) . We speculated, therefore, that locally produced M-CSF regulated proliferation of Ishikawa cells through activation of the M-CSF receptor (M-CSFr) (Croxtall et al., 1992 factor a (TNF-oc) (1, 2.5 and 5 ng ml-'), 8-bromo cAMP (5, 7.5 and 10 mM) or phorbol 12-myristate 13-acetate (TPA, 0.5 and 1 mM) for 24 h. Media were blotted onto zeta-probe membrane (Bio-Rad) by microfiltration, blocked in 5% milk powder solution, washed and incubated with rabbit antihuman M-CSF polyclonal antibody at a final dilution of 1:7500 (Genzyme Corporation). The immunoblots were visualised using alkaline phosphatase (Bio-Rad) according to the manufacturer's specifications. In preliminary experiments this procedure detected rhM-CSF but not IL-I1,, IL-2, granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage colony-stimulating factor (GM-CSF).
Infection of cells with fms constructs
The retroviral construct vsn2c-fms contains the complete cDNA for the human M-CSFr, whereas vsn2v-fms carries an oncogenic derivative, and was made previously (Dibb et al., 1990) . Retroviral construct vsn2c-fmsK612A was prepared here and is otherwise identical to vsn2c-fms except that the lysine residue 612 of the M-CSFr (Coussens et al., 1986) was changed to alanine by oligo-directed mutagenesis using the oligonucleotide TGCTGTCCTGGCCGTGGCTGTGA. Ishikawa cells were infected by the addition of supernatant from the retroviral packaging cell line PA317 that was separately transfected with each of the retroviral constructs vsn2; vsn2c-fms; vsn2v-fms and vsn2c-fmsK612A, as previously described (Baker et al., 1994 (Figure 3a) . The Cell number (x10-3) 300 Figure 2 M-CSF immunoreactivity is inversely proportional to cell density. Ishikawa cells were plated at increasing concentrations in serum-containing medium and then changed to serumfree conditions for 4 days to achieve the final cell density indicated. Medium was analysed for M-CSF immunoreactivity at the end of the culture period. Regression analysis of arbitrary densitometric units vs cell density indicated a correlation coefficient (r2) of 0.93 (P<0.001). (Figure 4, lane 4) . The failure to detect the mature form of c-fms in Ishikawa cells is unlikely to be due to a defect in the processing machinery of these cells because we observed the mature form of the M-CSFr in cells that overexpress the oncogene v-fms following infection with vsn2v-fms (Figure 4, lane 3) . Autophosphorylation of M-CSFr, owing to its intrinsic kinase activity, is a reliable indicator of its relative level of expression (Downing et al., 1989) associated with its internalisation and the disappearance of the mature form of the receptor (Downing et al., 1989; Sariban et al., 1989) . The relatively low abundance of the mature M-CSFr in Ishikawa cells (Figure 4 ) is therefore consistent with its turnover as a result of M-CSF stimulation. However, we have not as yet ruled out the alternative possibility that the mature form of the M-CSFr is regulated in these cells by the activity of protein kinase C, which is also known to influence M-CSFr activity, but by a mechanism independent of that stimulated by M-CSF (Downing et al., 1989) . The ability of the loss-of-function mutant M-CSFr, encoded by vsn2K612A, to retard the growth of Ishikawa cells (Figure 3b ) further strengthens the proposal that the growth of Ishikawa cells is responsive to, but not dependent upon, endogenously produced M-CSF. The mutant M-CSFr presumably inhibits M-CSF-induced growth by forming inactive heterodimers with the normal cellular M-CSFr. However, the alternative possibility that homodimeric, mutant, loss-of-function M-CSF receptors may act as a sink for endogenous M-CSF also needs to be considered. Regardless of the mechanism involved the data provide evidence of the importance of activation of M-CSF signalling pathways in the proliferation of endometrial cancer cells.
Detection of M-CSF in the conditioned medium of Ishikawa cells, under conditions in which there is no other source, indicates that the M-CSF transcript previously detected in these cells (Croxtall et al., 1991) (Sherman et al., 1990) . Although cAMP was not used in combination with TNF in the present study, its ability to induce M-CSF suggests that it would be unlikely to antagonise the effects of TNF in Ishikawa cells. Such stimulation of M-CSF by cAMP is more typical of the response observed in endothelial cells (Parhami et al., 1993) . These observations on the regulation of M-CSF in endometrial cancer cells suggest the potential for locally produced endometrial TNF and elevators of cellular cAMP to influence the M-CSF/fms autocrine loop. At present the molecular variants of the M-CSF transcripts in Ishikawa cells have not been analysed and it remains to be determined whether there is co-expression of species that encode secreted and membrane-bround protein .
Extrapolation of this data to the in vivo situation suggests that there is a potential functional consequence to the coexpression of M-CSF and c-fms in the majority of endometrial carcinomas. Taken together with evidence of the role of this loop in stimulating cellular invasion (Filderman et al., 1992) it seems likely that deregulation of M-CSF/c-fms expression and/or function has a pivotal role in growth and metastasis of endometrial cancer. The ability of interactive signalling pathways to regulate the expression of M-CSF, as shown here (Figure 1) , and the capacity of such signalling pathways also to be involved in the regulation of cfms expression (Yue et al., 1993) , provide avenues to explore the molecular mechanism underlying such overexpression in endometrial and ovarian cancer.
